MedTrace Logo

APG-1387 Study of Safety, Tolerability ,PK/PD in Patients With Chronic Hepatitis B

NCT03585322 · Status: COMPLETED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 49

Last updated 2021-11-08

No results posted yet for this study

Summary

This study is a Multiple Ascending Dose study to Explore the Tolerability, Safety and Pharmacokinetics/Pharmacodynamics of APG-1387 in Chronic Hepatitis B Patients.

Conditions

Interventions

DRUG

APG-1387 for Injection

Multiple dose cohorts, 30 minute IV infusion, once weekly for 4 weeks .

Sponsors & Collaborators

  • HealthQuest Pharma Inc.

    collaborator INDUSTRY

  • Ascentage Pharma Group Inc.

    lead INDUSTRY

Principal Investigators

  • Yifan Zhai, M.D., Ph.D. · Ascentage Pharma Group Inc.

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Max Age
65 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2018-07-04
Primary Completion
2021-10-15
Completion
2021-10-15

Countries

  • China

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT03585322 on ClinicalTrials.gov